EXHIBIT 99.1

This restricted stock unit award was granted to
Michael Eggenberg, a director of Xtant Medical
Holdings, Inc. (Xtant) who is an employee of
OrbiMed Advisors LLC (Advisors), a registered
adviser under the Investment Advisors Act of 1940,
as amended, who was designated by Advisors to sit
on the Xtant's board of directors. Upon vesting of
the restricted stock unit award, ownership of the
shares underlying the restricted stock unit award
will be transferred to ROS Acquisition Offshore LP
(ROS Acquisition) and OrbiMed Royalty Opportunities
II, LP (ORO II). Advisors is the investment manager
of ROS Acquisition. Advisors is also the investment
manager of Royalty Opportunities S.a.r.l., of which
ROS Acquisition is a wholly-owned subsidiary.
OrbiMed ROF II LLC (ROF II) is the sole general
partner of ORO II, and Advisors is the sole managing
member of ROF II. By virtue of such relationships,
Advisors and ROF II may be deemed to have voting and
investment power with respect to the securities held
by ROS Acquisition and ORO II and, as a result, may
be deemed to have beneficial ownership over such
securities. Advisors exercises its investment and
voting power through a management committee comprised
of Carl L. Gordon, Sven H. Borho, and Jonathan T.
Silverstein, each of whom disclaims beneficial
ownership of the securities held by ROS Acquisition
and ORO II.